Introduction {#H1-1-ZOI200159}
============

In the United States, the US Food and Drug Administration (FDA) issues approvals for new drugs and biologics that have demonstrated safety and efficacy in "adequate and well-controlled studies."^[@zoi200159r1]^ Pivotal trials are the most critical of these trials, often identified directly by FDA reviewers as the basis for approval and described in detail in FDA approval packages.^[@zoi200159r1]^ Early guidance suggested that at least 2 such trials were required for approval,^[@zoi200159r2]^ but the FDA has maintained a flexible interpretation, taking into consideration the ethical acceptability of conducting additional trials or the rarity of diseases when determining the sufficient threshold for safety and efficacy.^[@zoi200159r3]^ As a result, the quantity and quality of evidence supporting recent drug approvals is variable, both in terms of the number of pivotal trials and their design features, such as randomization, blinding, choice of comparators and end points, number of treated patients, and trial duration.^[@zoi200159r4],[@zoi200159r5],[@zoi200159r6]^

Potentially contributing to this variability is the increasing number of special regulatory programs available to the FDA during the past 30 years, now including Fast Track (1988, in statute 1997), Priority Review (1992), Accelerated Approval (1992), and Breakthrough Therapy designation (2012). Many of these programs codify special evidentiary standards acceptable for FDA approval of certain drugs and biologics, such as the use of surrogate end points (Accelerated Approval) and the acceptability of single trials as the basis of approval (Fast Track),^[@zoi200159r7],[@zoi200159r8]^ with the goal of promoting earlier market availability of certain therapies, such as those addressing an unmet need or those treating serious or life-threatening conditions (eTable 1 in the [Supplement](#note-ZOI200159-1-s){ref-type="supplementary-material"}). As these new programs are conformed to the regulatory environment in addition to existing programs, such as orphan designation (1983) for rare diseases,^[@zoi200159r7]^ it is critical to understand their potential influence on the quality of evidence supporting the new drugs and biologics that clinicians prescribe to their patients.

To address this question, we examined the clinical evidence supporting FDA approval of new drugs and biologics in the following 3-year periods, selected to illustrate the step-wise statutory implementation of the special regulatory programs across 3 decades: 1995 to 1997, 2005 to 2007, and 2015 to 2017. We characterized all new drug and biologic approvals within each given year as well as the pivotal trials supporting these approvals and determined whether trial design features differed by time period, including use of randomization, blinding, types of comparators, types of primary end points, number of treated patients, and trial duration. These findings could offer important insights into the influence of special regulatory programs on the FDA's evidentiary standards for new drugs and biologics over time as well as helping patients and clinicians better understand whether the clinical evidence supporting FDA approvals has changed.

Methods {#H1-2-ZOI200159}
=======

This study was prepared in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline for cross-sectional studies. The study did not require institutional review board approval or patient informed consent because it was based on publicly available information and involved no patient records.

Sample Construction {#H2-1-ZOI200159}
-------------------

The FDA lists all new drug applications and biologic licensing applications on the Drugs\@FDA database.^[@zoi200159r9]^ Using a previously described method,^[@zoi200159r5]^ we identified new drugs and biologics (eg, new molecular entities or new biologic drugs) approved during the periods of 1995 to 1997, 2005 to 2007, and 2015 to 2017, excluding new formulations, generics, and nontherapeutic agents (eg, diagnostic and contrast agents). We obtained the complete action package for the original approval of each therapeutic, either through the Drugs\@FDA database or, for therapeutics approved from 1995 to 1997, through a Freedom of Information Act request.

Therapeutic Indication and Regulatory Characteristics {#H2-2-ZOI200159}
-----------------------------------------------------

Based on information from the approval package, we classified each novel therapeutic by period of approval and product type (small-molecule drug or biologic). Using information available in the approval packages and from public listings available on the FDA website, we identified whether each therapeutic was evaluated through a special regulatory program (Priority Review, Accelerated Approval, Fast Track, Breakthrough Therapy).^[@zoi200159r10],[@zoi200159r11],[@zoi200159r12],[@zoi200159r13]^ These special regulatory programs are used for therapeutics that are intended to address unmet medical needs for serious or life-threatening conditions.^[@zoi200159r14]^ Data on certain special regulatory programs were not available in all years; data for Fast Track were only available after 1997, when it was codified by the 1997 Food and Drug Administration Modernization Act, and Breakthrough Therapy was introduced in 2012 by the Food and Drug Administration Safety and Innovation Act.^[@zoi200159r15]^

Using information available in the approval packages, we identified the indications for each novel therapeutic at the time of initial approval. We classified these into 1 of 8 therapeutic areas, based on the World Health Organization Anatomical Therapeutic Classification System.^[@zoi200159r16]^ Using the Orphan Products Designation Database, we also determined whether these originally approved indications had been granted orphan status, a designation granted at sponsor request to drugs for indications for which there are 200 000 or fewer patients in the United States or those for which alternative therapeutic options are often not available.^[@zoi200159r17]^

Trial Characteristics {#H2-3-ZOI200159}
---------------------

We followed a previously described method to identify and characterize the pivotal efficacy trials used as the basis of approval for each indication of each new drug or biologic (eAppendix in the [Supplement](#note-ZOI200159-1-s){ref-type="supplementary-material"}).^[@zoi200159r4],[@zoi200159r5]^ Briefly, these were trials explicitly labeled in FDA medical reviews as pivotal. In cases in which trials were not explicitly labeled, we first collected all trials submitted for evaluation in the FDA medical review and then identified as pivotal those trials described by FDA medical reviewers as essential to approval, those prioritized within the review with substantial discussion of study design (eg, thorough description of study protocol and inclusion and exclusion criteria), or those prioritized within the review with independent analysis of study results (ie, not pooled with other studies). Additionally, any new efficacy trial reviewed as part of a resubmitted application was considered pivotal to approval.

For each identified trial, we determined its use of randomization and blinding, categorized as randomized vs nonrandomized and double-blinded vs not double-blinded, respectively. Next, we categorized use of a comparator as active treatment, placebo control, or none. We categorized primary trial end points as clinical end points, clinical scales, or surrogate end points using a previously developed framework.^[@zoi200159r5],[@zoi200159r18]^ Briefly, clinical end points, such as death or hospitalization, are those that measure patient-reported outcomes, function, or survival; clinical scales, such as the visual analog scale for pain, represent ordinal characterizations of symptoms; and surrogate end points, such as hemoglobin A~1c~ level, represent biomarkers expected to predict clinical benefit. We determined the number of treated patients by abstracting the number of patients included in intention-to-treat analyses. We also determined the duration of each trial. For time-driven end points, duration was defined as the time of primary end point measurement, such as hemoglobin A~1c~ level at 24 weeks. For event-driven end points, such as progression-free survival, duration was defined as the median follow-up time for participants or a weighted average of the median follow-up time in cases in which it differed between trial groups. Initial abstraction was performed by 3 of us (A.D.Z., J.P., and N.S.D.).

Statistical Analysis {#H2-4-ZOI200159}
--------------------

We used descriptive statistics to characterize the sample of new drugs and biologics and their indications for use and to characterize the features of their supporting pivotal trials. We used χ^2^ tests for trend to compare trial characteristics across the 3 periods and Spearman rank tests to compare trial characteristics between the 1995 to 1997 and the 2015 to 2017 periods, both at the level of individual pivotal trials and aggregate pivotal trial evidence supporting each indication approval. To prevent undercounting in cases with missing data, analyses aggregated by indication included only those indications for which pivotal trial characteristic reporting was complete. We stratified analyses by use of any special regulatory program, as defined earlier, and by use of orphan designation.

We conducted sensitivity analyses for individual pivotal trials and aggregated indication approval characteristics to evaluate the association of additional covariates with the observed changes in clinical trial characteristics over time, including product type (small-molecule drug vs biologic), therapeutic area, and expected length of treatment. Expected length of treatment was categorized as acute for drugs with expected lengths of use of less than 1 month, intermediate for those between 1 month and 2 years, and chronic for those longer than 2 years. We also conducted sensitivity analyses examining the individual regulatory programs spanning 3 periods (eg, Priority Review and Accelerated Approval). All statistical tests were 2-tailed and used the Bonferroni method to adjust *P* values to account for multiple comparisons. Statistical significance was set at *P* \< .025. All analyses were conducted using R version 3.5.1 (R Project for Statistical Computing).

Results {#H1-3-ZOI200159}
=======

We identified 273 new drugs and biologics approved by the FDA for 339 indications across 3 periods: 107 drugs (39.2%) for 157 indications (46.3%) from 1995 to 1997, 57 (20.9%) drugs for 64 indications (18.9%) from 2005 to 2007, and 109 drugs (39.9%) for 118 indications (34.8%) from 2015 to 2017. Product and indication characteristics differed across these periods ([Table 1](#zoi200159t1){ref-type="table"}). The proportion of biologics among new approvals has increased (3 \[2.8%\] in 1995-1997; 8 \[14.0%\] in 2005-2007; and 30 \[27.5%\] in 2015-2017; *P* \< .001) as have the proportion of approvals using any special regulatory program (37 \[34.6%\] in 1995-1997; 33 \[57.9%\] in 2005-2007; and 70 \[64.2%\] in 2015-2017; *P* \< .001) or orphan designation (20 \[12.7%\] in 1995-1997; 17 \[26.6%\] in 2005-2007; and 45 \[38.1%\] in 2015-2017; *P* \< .001). The therapeutic areas associated with new indication approvals have shifted, with the most common therapeutic area being infectious disease from 1995 to 1997 (53 \[33.8%\]) and cancer from 2015 to 2017 (32 \[27.1%\]) ([Table 1](#zoi200159t1){ref-type="table"}).

###### Characteristics of New Drugs and Biologics Approved by the US Food and Drug Administration From 1995 to 1997, 2005 to 2007, and 2015 to 2017

  Characteristic                             No. (%)            *P* value                           
  ------------------------------------------ ------------------ ----------------- ----------------- --------
  Indications, median (IQR) \[range\], No.   1 (1-1) \[1-14\]   1 (1-1) \[1-6\]   1 (1-1) \[1-2\]   .03
  Agent type                                                                                        
  Drug                                       104 (97.2)         49 (86.0)         79 (72.5)         \<.001
  Biologic                                   3 (2.8)            8 (14.0)          30 (27.5)         \<.001
  Special regulatory program                                                                        
  Any                                        37 (34.6)          33 (57.9)         70 (64.2)         \<.001
  Priority Review                            36 (33.6)          31 (54.4)         67 (61.5)         \<.001
  Accelerated Approval                       12 (11.2)          12 (21.1)         18 (16.5)         .28
  Fast Track                                 NA                 14 (24.6)         39 (35.8)         NA
  Breakthrough Therapy                       NA                 NA                34 (31.2)         NA
  FDA-approved indications, No.              157                64                118               NA
  Therapeutic area                                                                                  
  Infectious disease                         53 (33.8)          16 (25.0)         17 (14.4)         \<.001
  Cancer                                     17 (10.8)          11 (17.2)         32 (27.1)         \<.001
  Cardiovascular, diabetes, and/or lipids    26 (16.6)          10 (15.6)         17 (14.4)         .63
  Other                                      61 (38.9)          27 (42.2)         52 (44.1)         .38
  Orphan status                              20 (12.7)          17 (26.6)         45 (38.1)         \<.001

Abbreviations: IQR, interquartile range; NA, not applicable.

Features of Individual Pivotal Trials {#H2-5-ZOI200159}
-------------------------------------

We identified a total of 795 pivotal trials supporting the new drugs and biologics in our sample: 401 trials (50.4%) from 1995 to 1997, 141 trials (17.7%) from 2005 to 2007, and 253 trials (31.8%) from 2015 to 2017. Of these pivotal trials, most were randomized ([Table 2](#zoi200159t2){ref-type="table"}), although randomization decreased from 93.6% (95% CI, 90.7%-95.8%) between 1995 and 1997 to 82.2% (95% CI, 74.9%-88.2%) between 2005 and 2007 and 82.2% (95% CI, 76.9%-86.7%) between 2015 and 2017 (*P* \< .001). Likewise, most trials were double-blinded, although double-blinding decreased from 79.4% (95% CI, 75.0%-83.3%) between 1995 and 1997 to 67.4% (95% CI, 58.8%-75.0%) between 2005 and 2007 and 67.6% (95% CI, 61.4%-73.3%) between 2015 and 2017 (*P* \< .001). Choice of comparators differed by time period; use of active comparators decreased (44.1% \[95% CI, 39.2%-49.2%\] in 1995-1997; 34.0% \[95% CI, 26.3%-42.5%\] in 2005-2007; and 29.2% \[23.7%-35.3%\] in 2015-2017; *P* \< .001), while single-group trials increased (8.5% \[95% CI, 5.9%-11.6%\] in 1995-1997; 17.7% \[11.8%-25.1%\] in 2005-2007; and 17.8% \[13.3%-23.1%\] in 2015-2017; *P* \< .001). Sensitivity analyses were conducted examining rates of randomization and blinding only among trials using active or placebo comparators (ie, non--single-group trials) and showed no changes over time (eTable 2 in the [Supplement](#note-ZOI200159-1-s){ref-type="supplementary-material"}).

###### Characteristics of Pivotal Trials Supporting New Drugs and Biologics Approved by the US Food and Drug Administration From 1995 to 1997, 2005 to 2007, and 2015 to 2017, Overall and Stratified by Special Regulatory Program Use and Orphan Designation

  Characteristic                                             Trials, No.   \% (95% CI)                                                                                                                          
  ---------------------------------------------------------- ------------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------
  **Overall**                                                                                                                                                                                                   
  1995-1997                                                  401           93.6 (90.7-95.8)   79.4 (75.0-83.3)   44.1 (39.2-49.2)   47.4 (42.4-52.4)   8.5 (5.9-11.6)     43.8 (38.8-48.8)   8.0 (5.5-11.1)     48.3 (43.3-53.3)
  2005-2007                                                  141           82.2 (74.9-88.2)   67.4 (58.8-75.0)   34.0 (26.3-42.5)   48.2 (39.7-56.8)   17.7 (11.8-25.1)   28.4 (21.1-36.6)   11.3 (6.6-17.8)    60.3 (51.7-68.4)
  2015-2017                                                  253           82.2 (76.9-86.7)   67.6 (61.4-73.3)   29.2 (23.7-35.3)   53.0 (46.6-59.2)   17.8 (13.3-23.1)   23.3 (18.3-29.0)   17.4 (12.9-22.6)   59.3 (53.0-65.4)
  3-Way *P*value                                             NA            \<.001             \<.001             \<.001             .17                \<.001             \<.001             \<.001             .004
  2-Way *P*value[^a^](#zoi200159t2n1){ref-type="table-fn"}   NA            \<.001             \<.001             \<.001             \<.001                                                                      
  **Special regulatory program**                                                                                                                                                                                
  Any                                                                                                                                                                                                           
  1995-1997                                                  89            80.9 (71.2-88.5)   74.4 (63.6-83.4)   37.6 (27.4-48.8)   43.5 (32.8-54.7)   18.8 (11.1-28.8)   20.0 (12.1-30.1)   5.9 (1.9-13.2)     75.3 (64.7-84.0)
  2005-2007                                                  64            75.0 (62.6-85.0)   56.3 (43.3-68.6)   35.9 (24.3-48.9)   39.1 (27.1-52.1)   25.0 (15.0-37.4)   37.5 (25.7-50.5)   7.8 (2.6-17.3)     54.7 (41.7-67.2)
  2015-2017                                                  128           67.2 (58.3-75.2)   53.9 (44.9-62.8)   23.4 (16.4-31.7)   43.8 (35.0-52.8)   32.8 (24.8-41.7)   19.5 (13.1-27.5)   13.3 (7.9-20.4)    67.2 (58.3-75.2)
  3-Way *P*value                                             NA            .02                .004               .02                .92                .02                .71                .07                .32
  2-Way *P*value[^a^](#zoi200159t2n1){ref-type="table-fn"}   NA            .004               .003               .03                .22                                                                         
  None                                                                                                                                                                                                          
  1995-1997                                                  316           96.1 (93.3-98.0)   80.7 (75.9-84.9)   45.9 (40.3-51.6)   48.4 (42.8-54.1)   5.7 (3.4-8.9)      50.2 (44.5-55.8)   8.6 (5.7-12.2)     41.3 (35.8-46.9)
  2005-2007                                                  77            88.3 (79.0-94.5)   76.6 (65.6-85.5)   32.5 (22.2-44.1)   55.8 (44.1-67.2)   11.7 (5.5-21.0)    22.1 (13.4-33.0)   14.3 (7.4-24.1)    64.9 (53.2-75.5)
  2015-2017                                                  125           97.6 (93.1-99.5)   81.6 (73.7-88.0)   35.2 (26.9-44.2)   62.4 (53.3-70.9)   2.4 (0.5-6.9)      27.2 (19.6-35.9)   21.6 (14.7-29.8)   51.2 (42.1-60.2)
  3-Way *P*value                                             NA            .92                .96                .02                .007               .38                \<.001             \<.001             .014
  2-Way *P*value[^a^](#zoi200159t2n1){ref-type="table-fn"}   NA            .44                .83                .02                \<.001                                                                      
  **Orphan designation**                                                                                                                                                                                        
  Yes                                                                                                                                                                                                           
  1995-1997                                                  36            80.6 (62.5-92.5)   61.3 (42.2-78.2)   25.8 (11.9-44.6)   45.2 (27.3-64.0)   29.0 (14.2-48.0)   48.4 (30.2-66.9)   9.7 (2.0-25.8)     41.9 (24.5-60.9)
  2005-2007                                                  24            45.8 (25.6-67.2)   29.2 (12.6-51.1)   12.5 (2.7-32.4)    33.3 (15.6-55.3)   54.2 (32.8-74.4)   37.5 (18.8-59.4)   0.0 (0.0-14.2)     62.5 (40.6-81.2)
  2015-2017                                                  63            52.4 (39.4-65.1)   39.7 (27.6-52.8)   6.3 (1.8-15.5)     46.0 (33.4-59.1)   47.6 (34.9-60.6)   19.0 (10.2-30.9)   7.9 (2.6-17.6)     73.0 (60.3-83.4)
  3-Way *P*value                                             NA            .02                .09                .009               .80                .13                .003               .94                .004
  2-Way *P*value[^a^](#zoi200159t2n1){ref-type="table-fn"}   NA            .009               .05                .02                .009                                                                        
  No                                                                                                                                                                                                            
  1995-1997                                                  372           94.7 (91.9-96.8)   80.9 (76.5-84.9)   45.7 (40.5-50.9)   47.6 (42.4-52.8)   6.8 (4.4-9.8)      43.4 (38.2-48.6)   7.9 (5.3-11.1)     48.8 (43.6-54.0)
  2005-2007                                                  117           89.7 (82.8-94.6)   75.2 (66.4-82.7)   38.5 (29.6-47.9)   51.3 (41.9-60.6)   10.3 (5.4-17.2)    26.5 (18.8-35.5)   13.7 (8.0-21.3)    59.8 (50.4-68.8)
  2015-2017                                                  190           92.1 (87.3-95.5)   76.8 (70.2-82.6)   36.8 (30.0-44.1)   55.3 (47.9-62.5)   7.9 (4.5-12.7)     24.7 (18.8-31.5)   20.5 (15.0-27.0)   54.7 (47.4-62.0)
  3-Way *P*value                                             NA            .17                .21                .04                .08                .53                \<.001             \<.001             .12
  2-Way *P*value[^a^](#zoi200159t2n1){ref-type="table-fn"}   NA            .22                .26                .14                \<.001                                                                      

Abbreviation: NA, not applicable.

Two-way *P* value was calculated for differences between 1995 to 1997 and 2015 to 2017 periods.

Choice of primary end point also differed over time; use of clinical end points decreased (43.8% \[95% CI, 38.8%-48.8%\] in 1995-1997; 28.4% \[95% CI, 21.1%-36.6%\] in 2005-2007; and 23.3% \[18.3%-29.0%\] in 2015-2017; *P* \< .001), while the use of surrogate end points increased (48.3% \[95% CI, 43.3%-53.3%\] in 1995-1997; 60.3% \[51.7%-68.4%\] in 2005-2007; and 59.3% \[53.0%-65.4%\] in 2015-2017; *P* = .004). Median (interquartile range \[IQR\]) number of treated patients in each pivotal trial also increased (277 \[150-442\] in 1995-1997; 404 \[189-622\] in 2005-2007; and 467 \[209-722\] in 2015-2017; *P* \< .001), as did median (IQR) trial duration (11.0 \[4.9-24.0\] weeks in 1995-1997; 16.0 \[6.0-26.0\] weeks in 2005-2007; and 24.0 \[12.0-37.6\] weeks in 2015-2017; *P* \< .001) ([Table 3](#zoi200159t3){ref-type="table"}).

###### Number of Treated Patients and Duration of Pivotal Trials Supporting New Drugs and Biologics Approved by the US Food and Drug Administration From 1995 to 1997, 2005 to 2007, and 2015 to 2017, Overall and Stratified by Special Regulatory Program Use and Orphan Designation

  Characteristic                                             Trials, No.   Treated patients, median (IQR), No.   Duration, median (IQR), wk   
  ---------------------------------------------------------- ------------- ------------------------------------- ---------------------------- ------------------
  **Overall**                                                                                                                                 
  1995-1997                                                  401           277 (150-442)                         168 (91-274)                 11.0 (4.9-24.0)
  2005-2007                                                  141           404 (189-622)                         243 (136-381)                16.0 (6.0-26.0)
  2015-2017                                                  253           467 (209-722)                         279 (143-451)                24.0 (12.0-37.6)
  3-Way *P*value                                             NA            \<.001                                \<.001                       \<.001
  2-Way *P*value[^a^](#zoi200159t3n1){ref-type="table-fn"}   NA            \<.001                                \<.001                       \<.001
  **Special regulatory program**                                                                                                              
  Any                                                                                                                                         
  1995-1997                                                  89            236 (95-424)                          148 (64-259)                 24.0 (16.0-52.0)
  2005-2007                                                  64            329 (115-605)                         225 (106-336)                17.0 (9.7-28.3)
  2015-2017                                                  128           239 (121-658)                         177 (87-366)                 24.0 (12.0-50.3)
  3-Way *P*value                                             NA            .10                                   .03                          .61
  2-Way *P*value[^a^](#zoi200159t3n1){ref-type="table-fn"}   NA            .07                                   .02                          .33
  None                                                                                                                                        
  1995-1997                                                  316           290 (165-451)                         182 (97-289)                 8.0 (4.0-16.0)
  2005-2007                                                  77            455 (273-651)                         254 (163-409)                12.0 (5.0-26.0)
  2015-2017                                                  125           546 (427-931)                         329 (244-574)                24.0 (12.0-26.0)
  3-Way *P*value                                             NA            \<.001                                \<.001                       \<.001
  2-Way *P*value[^a^](#zoi200159t3n1){ref-type="table-fn"}   NA            \<.001                                \<.001                       \<.001
  **Orphan designation**                                                                                                                      
  Yes                                                                                                                                         
  1995-1997                                                  36            155 (51-270)                          94 (28-199)                  24.5 (7.9-78.2)
  2005-2007                                                  24            92 (55-190)                           76 (42-150)                  21.3 (8.5-52.0)
  2015-2017                                                  63            129 (69-378)                          113 (60-242)                 34.6 (14.9-70.7)
  3-Way *P*value                                             NA            .71                                   .20                          .08
  2-Way *P*value[^a^](#zoi200159t3n1){ref-type="table-fn"}   NA            .98                                   .30                          .19
  No                                                                                                                                          
  1995-1997                                                  372           290 (158-446)                         179 (97-285)                 8.1 (4.8-24.0)
  2005-2007                                                  117           471 (296-652)                         265 (173-401)                12.0 (5.2-26.0)
  2015-2017                                                  190           543 (352-818)                         323 (220-503)                20.0 (12.0-26.0)
  3-Way *P*value                                             NA            \<.001                                \<.001                       \<.001
  2-Way *P*value[^a^](#zoi200159t3n1){ref-type="table-fn"}   NA            \<.001                                \<.001                       \<.001

Abbreviations: IQR, interquartile range; NA, not applicable.

Two-way *P* value was calculated for differences between 1995 to 1997 and 2015 to 2017 time periods.

Features of Aggregated Pivotal Trials Supporting Indication Approvals {#H2-6-ZOI200159}
---------------------------------------------------------------------

Overall, 7 of 339 indication approvals (2.0%) were not supported by any pivotal trial (eTable 3 in the [Supplement](#note-ZOI200159-1-s){ref-type="supplementary-material"}). Of the 332 indication approvals (98.0%) supported by pivotal trials, 293 (88.3%) had complete reporting of all abstracted pivotal trial characteristics within FDA documentation (124 \[82.7%\] in 1995-1997; 63 \[98.4%\] in 2005-2007; and 106 \[89.8%\] in 2015-2017) (eTable 4 and eTable 5 in the [Supplement](#note-ZOI200159-1-s){ref-type="supplementary-material"}). Among these 293 indication approvals, the proportion supported by at least 2 pivotal trials decreased over time (80.6% \[95% CI, 72.6%-87.2%\] in 1995-1997; 60.3% \[47.2%-72.4%\] in 2005-2007; and 52.8% \[42.9%-62.6%\] in 2015-2017; *P* \< .001) ([Table 4](#zoi200159t4){ref-type="table"}). The proportion of indication approvals supported only by single-group trials increased over time (4.0% \[1.3%-9.2%\] in 1995-1997; 12.7% \[5.6%-23.5%\] in 2005-2007; and 17.0% \[10.4%-25.5%\] in 2015-2017; *P* = .001). The proportion of indication approvals supported only by trials using surrogate end points was not statistically different over time nor was the median aggregated number of treated patients ([Table 4](#zoi200159t4){ref-type="table"} and [Table 5](#zoi200159t5){ref-type="table"}). The proportion of indication approvals with at least 1 trial of 6 months' duration increased (25.8% \[95% CI, 18.4%-34.4%\] in 1995-1997; 34.9% \[95% CI, 23.3%-48.0%\] in 2005-2007; and 46.2% \[95% CI, 36.5%-56.2%\] in 2015-2017; *P* = .001).

###### Characteristics of Aggregated Pivotal Trials Supporting US Food and Drug Administration Indication Approvals for New Drugs and Biologics From 1995 to 1997, 2005 to 2007, and 2015 to 2017, Overall and Stratified by Special Regulatory Program Use and Orphan Designation

  Characteristic                                             Trials, No.   \% (95% CI)                                                                                                         
  ---------------------------------------------------------- ------------- ------------------ ------------------ ------------------ -------------------- ------------------ ------------------ ------------------
  **Overall**                                                                                                                                                                                  
  1995-1997                                                  124           80.6 (72.6-87.2)   25.8 (18.4-34.4)   18.5 (12.1-26.5)   96.0 (90.8-98.7)     4.0 (1.3-9.2)      60.5 (51.3-69.1)   39.5 (30.9-48.7)
  2005-2007                                                  63            60.3 (47.2-72.4)   34.9 (23.3-48.0)   19.0 (10.2-30.9)   87.3 (76.5-94.4)     12.7 (5.6-23.5)    49.2 (36.4-62.1)   50.8 (37.9-63.6)
  2015-2017                                                  106           52.8 (42.9-62.6)   46.2 (36.5-56.2)   35.8 (26.8-45.7)   83.0 (74.5-89.6)     17.0 (10.4-25.5)   54.7 (44.8-64.4)   45.3 (35.6-55.2)
  3-Way *P*value                                             NA            .001               .001               .003               .001                 .36                                   
  2-Way *P*value[^a^](#zoi200159t4n1){ref-type="table-fn"}   NA            .001               .001               .003               .001                 .38                                   
  **Special regulatory program**                                                                                                                                                               
  Any                                                                                                                                                                                          
  1995-1997                                                  32            75.0 (56.6-88.5)   50.0 (31.9-68.1)   31.3 (16.1-50.0)   87.5 (71.0-96.5)     12.5 (3.5-29.0)    34.4 (18.6-53.2)   65.6 (46.8-81.4)
  2005-2007                                                  36            52.8 (35.5-69.6)   36.1 (20.8-53.8)   25.0 (12.1-42.2)   77.8 (60.8-89.9)     22.2 (10.1-39.2)   47.2 (30.4-64.5)   52.8 (35.5-69.6)
  2015-2017                                                  63            38.1 (26.1-51.2)   50.8 (37.9-63.6)   36.5 (24.7-49.6)   73.0 (60.3-83.4)     27.0 (16.6-39.7)   44.4 (31.9-57.5)   55.6 (42.5-68.1)
  3-Way *P*value                                             NA            .001               .74                .48                .11                  .42                                   
  2-Way *P*value[^a^](#zoi200159t4n1){ref-type="table-fn"}   NA            .001               .95                .62                .11                  .35                                   
  None                                                                                                                                                                                         
  1995-1997                                                  92            82.7 (73.3-89.7)   17.4 (10.3-26.7)   14.1 (7.7-23.0)    98.9 (94.1-100.0)    1.1 (0.0-5.9)      69.6 (59.1-78.7)   30.4 (21.3-40.9)
  2005-2007                                                  27            70.4 (49.8-86.2)   33.3 (16.5-54.0)   11.1 (2.4-29.2)    100.0 (87.2-100.0)   0.0 (0.0-12.8)     51.9 (31.9-71.3)   48.1 (28.7-68.1)
  2015-2017                                                  43            74.4 (58.8-86.5)   39.5 (25.0-55.6)   34.9 (21.0-50.9)   97.7 (87.7-99.9)     2.3 (0.0-12.3)     69.8 (53.9-82.8)   30.2 (17.2-46.1)
  3-Way *P*value                                             NA            .22                .004               .008               .62                  .80                                   
  2-Way *P*value[^a^](#zoi200159t4n1){ref-type="table-fn"}   NA            .27                .006               .006               .59                  .98                                   
  **Orphan designation**                                                                                                                                                                       
  Yes                                                                                                                                                                                          
  1995-1997                                                  11            72.7 (39.0-94.0)   54.5 (23.4-83.3)   36.4 (10.9-69.2)   81.8 (48.2-97.7)     18.2 (2.3-51.8)    81.8 (48.2-97.7)   18.2 (2.3-51.8)
  2005-2007                                                  17            23.5 (6.8-49.9)    52.9 (27.8-77.0)   41.2 (18.4-67.1)   58.8 (32.9-81.6)     41.2 (18.4-67.1)   47.1 (23.0-72.2)   52.9 (27.8-77.0)
  2015-2017                                                  38            23.7 (11.4-40.2)   63.2 (46.0-78.2)   44.7 (28.6-61.7)   65.8 (48.6-80.4)     34.2 (19.6-51.4)   36.8 (21.8-54.0)   63.2 (46.0-78.2)
  3-Way *P*value                                             NA            .008               .50                .61                .49                  .01                                   
  2-Way *P*value[^a^](#zoi200159t4n1){ref-type="table-fn"}   NA            .003               .62                .63                .32                  .10                                   
  No                                                                                                                                                                                           
  1995-1997                                                  113           81.4 (73.0-88.1)   23.0 (15.6-31.9)   16.8 (10.4-25.0)   97.3 (92.4-99.4)     2.7 (0.6-7.6)      58.4 (48.8-67.6)   41.6 (32.4-51.2)
  2005-2007                                                  46            73.9 (58.9-85.7)   28.3 (16.0-43.5)   10.9 (3.6-23.6)    97.8 (88.5-99.9)     2.2 (0.0-11.5)     50.0 (34.9-65.1)   50.0 (34.9-65.1)
  2015-2017                                                  68            69.1 (56.7-79.8)   36.8 (25.4-49.3)   30.9 (20.2-43.3)   92.6 (83.7-97.6)     7.4 (2.4-16.3)     64.7 (52.2-75.9)   35.3 (24.1-47.8)
  3-Way *P*value                                             NA            .06                .05                .04                .14                  .50                                   
  2-Way *P*value[^a^](#zoi200159t4n1){ref-type="table-fn"}   NA            .06                .05                .03                .14                  .40                                   

Abbreviation: NA, not applicable.

Two-way *P* value was calculated for differences between 1995 to 1997 and 2015 to 2017 time periods.

###### Number of Pivotal Efficacy Trials and Number of Treated Patients in Aggregated Pivotal Trials Supporting US Food and Drug Administration Indication Approvals of New Drugs and Biologics From 1995 to 1997, 2005 to 2007, and 2015 to 2017, Overall and Stratified by Special Regulatory Program Use and Orphan Designation

  Characteristic                                             Trials, No.   Pivotal efficacy trials, median (IQR), No.   Treated patients, median (IQR), aggregated No.   
  ---------------------------------------------------------- ------------- -------------------------------------------- ------------------------------------------------ -----------------
  **Overall**                                                                                                                                                            
  1995-1997                                                  124           2.0 (2.0-3.0)                                774 (464-1314)                                   490 (236-738)
  2005-2007                                                  63            2.0 (1.0-2.8)                                699 (218-1380)                                   416 (191-808)
  2015-2017                                                  106           1.0 (1.0-3.0)                                816 (199-2112)                                   523 (145-1303)
  3-Way *P*value                                             NA            .001                                         .89                                              .80
  2-Way *P*value[^a^](#zoi200159t5n1){ref-type="table-fn"}   NA            .001                                         .83                                              .73
  **Special regulatory program**                                                                                                                                         
  Any                                                                                                                                                                    
  1995-1997                                                  32            2.0 (1.4-3.0)                                618 (223-945)                                    384 (147-568)
  2005-2007                                                  36            2.0 (1.0-2.0)                                534 (166-979)                                    340 (119-544)
  2015-2017                                                  63            1.0 (1.0-2.0)                                404 (137-1076)                                   261 (101-710)
  3-Way *P*value                                             NA            .002                                         .40                                              .54
  2-Way *P*value[^a^](#zoi200159t5n1){ref-type="table-fn"}   NA            .001                                         .31                                              .47
  None                                                                                                                                                                   
  1995-1997                                                  92            2.0 (2.0-3.0)                                805 (531-1403)                                   514 (293-970)
  2005-2007                                                  27            2.0 (1.0-3.8)                                1167 (419-1835)                                  680 (244-1374)
  2015-2017                                                  43            2.0 (1.2-3.0)                                1740 (1047-2853)                                 1050 (565-1768)
  3-Way *P*value                                             NA            .41                                          .001                                             .001
  2-Way *P*value[^a^](#zoi200159t5n1){ref-type="table-fn"}   NA            .43                                          .001                                             .001
  **Orphan designation**                                                                                                                                                 
  Yes                                                                                                                                                                    
  1995-1997                                                  11            2.0 (1.2-2.0)                                260 (212-893)                                    153 (137-444)
  2005-2007                                                  17            1.0 (1.0-1.3)                                164 (73-422)                                     83 (42-273)
  2015-2017                                                  38            1.0 (1.0-1.1)                                196 (90-495)                                     134 (79-326)
  3-Way *P*value                                             NA            .02                                          .42                                              .72
  2-Way *P*value[^a^](#zoi200159t5n1){ref-type="table-fn"}   NA            .003                                         .08                                              .25
  No                                                                                                                                                                     
  1995-1997                                                  113           2.0 (2.0-3.0)                                811 (526-1369)                                   510 (283-791)
  2005-2007                                                  46            2.0 (1.0-3.0)                                1027 (474-1584)                                  577 (267-955)
  2015-2017                                                  68            2.0 (1.0-3.0)                                1646 (768-2668)                                  1019 (428-1568)
  3-Way *P*value                                             NA            .11                                          .001                                             .001
  2-Way *P*value[^a^](#zoi200159t5n1){ref-type="table-fn"}   NA            .14                                          .001                                             .001

Abbreviations: IQR, interquartile range; NA, not applicable.

Two-way *P*value was calculated for differences between 1995 to 1997 and 2015 to 2017 periods.

Aggregated Pivotal Trial Features Supporting Indication Approvals by Use of Special Regulatory Programs {#H2-7-ZOI200159}
-------------------------------------------------------------------------------------------------------

The proportion of new drug or biologic approvals using any special regulatory program (Priority Review, Accelerated Approval, Fast Track, or Breakthrough Therapy) increased over time, with 37 (34.6%) from 1995 to 1997, 33 (57.9%) from 2005 to 2007, and 70 (64.2%) from 2015 to 2017 (*P* \< .001) ([Table 1](#zoi200159t1){ref-type="table"}). Among indication approvals using any special regulatory program, the proportion supported by at least 2 pivotal trials decreased over time (75.0% \[95% CI, 56.6%-88.5%\] in 1995-1997; 52.8% \[95% CI, 35.5%-69.6%\] in 2005-2007; and 38.1% \[95% CI, 26.1%-51.2%\] in 2015-2017; *P* \< .001) ([Table 4](#zoi200159t4){ref-type="table"}). There were not statistically significant changes in the proportion supported only by single-group trials, supported only by trials using surrogate end points, supported by at least 1 trial of 6 months' duration, or in the median aggregated number of treated patients ([Table 4](#zoi200159t4){ref-type="table"} and [Table 5](#zoi200159t5){ref-type="table"}).

Among indication approvals not using any special regulatory program, there were not statistically significant changes in the proportion supported by at least 2 pivotal trials, supported only by single-group trials, or supported by trials using surrogate end points ([Table 4](#zoi200159t4){ref-type="table"}). However, the median (IQR) aggregated number of treated patients increased over time (805 \[531-1403\] in 1995-1997; 1167 \[419-1835\] in 2005-2007; and 1740 \[1047-2853\] in 2015-2017; *P* \< .001), as did the proportion supported by at least 1 trial of 6 months' duration (17.4% \[95% CI, 10.3%-26.7%\] in 1995-1997; 33.3% \[95% CI, 16.5%-54.0%\] in 2005-2007; and 39.5% \[25.0%-55.6%\] in 2015-2017; *P* = .004) ([Table 4](#zoi200159t4){ref-type="table"} and [Table 5](#zoi200159t5){ref-type="table"}).

Aggregated Pivotal Trial Features Supporting Indication Approvals by Orphan Designation Status {#H2-8-ZOI200159}
----------------------------------------------------------------------------------------------

The proportion of indication approvals receiving orphan designations increased over time, with 20 (12.7%) in 1995 to 1997, 17 (26.6%) in 2005 to 2007, and 45 (38.1%) in 2015 to 2017 (*P* \< .001) ([Table 1](#zoi200159t1){ref-type="table"}). Trends in the features of aggregated pivotal trials supporting indications over time differed when stratified by orphan designation status. Among orphan indications, the proportion of indication approvals supported by at least 2 pivotal trials decreased over time (72.7% \[95% CI, 39.0%-94.0%\] in 1995-1997; 23.5% \[6.8%-49.9%\] in 2005-2007; and 23.7% \[11.4%-40.2%\] in 2015-2017; *P* = .008) ([Table 4](#zoi200159t4){ref-type="table"}). The proportion of orphan indications supported only by single-group trials did not change, while those supported only by trials using surrogate end points increased over time (18.2% \[95% CI, 2.3%-51.8%\] in 1995-1997; 52.9% \[95% CI, 27.8%-77.0%\] in 2005-2007; and 63.2% \[95% CI, 46.0%-78.2%\] in 2015-2017; *P* = .01). The median aggregated number of treated patients for orphan indications did not differ over time nor did the proportion of indications with at least 1 trial of 6 months' duration ([Table 4](#zoi200159t4){ref-type="table"} and [Table 5](#zoi200159t5){ref-type="table"}).

In contrast, the proportion of nonorphan indications supported by at least 2 pivotal trials did not change over time nor did those supported only by single-group trials, those supported only by trials using surrogate end points, or those supported by at least 1 trial of 6 months' duration. Meanwhile, the median (IQR) aggregated number of treated patients increased (811 \[526-1369\] in 1995-1997; 1027 \[474-1584\] in 2005-2007; and 1646 \[768-2668\] in 2015-2017; *P* \< .001).

Sensitivity Analyses {#H2-9-ZOI200159}
--------------------

Observed changes in individual pivotal trial and aggregated indication approval characteristics when stratified by product type were consistent for small-molecule drugs and limited by small sample size for biologics. Observed changes when stratified by therapeutic area were largely consistent, although often limited by small sample size after stratification (eTables 6-9 in the [Supplement](#note-ZOI200159-1-s){ref-type="supplementary-material"}). When stratified by expected length of treatment, the observed trend of increasing clinical trial duration over time persisted for therapeutics with acute length but not for intermediate or chronic length of treatment (eTable 10 and eTable 11 in the [Supplement](#note-ZOI200159-1-s){ref-type="supplementary-material"}). The observed trends in aggregated indication approval characteristics were consistent when stratified by Priority Review and Accelerated Approval considered individually (eTable 12 and eTable 13 in the [Supplement](#note-ZOI200159-1-s){ref-type="supplementary-material"}) compared with special regulatory programs considered as a whole, as were trends when considering orphan designation as a special regulatory program (eTable 14 and eTable 15 in the [Supplement](#note-ZOI200159-1-s){ref-type="supplementary-material"}).

Discussion {#H1-4-ZOI200159}
==========

We reviewed all new drugs and biologics approved by the FDA from 1995 to 1997, from 2005 to 2007, and from 2015 to 2017 and found differences over time in the quality of evidence supporting their approval. The aggregated evidence supporting indication approvals has become less rigorous in some ways, with the proportion of approvals supported by the commonly understood standard of at least 2 pivotal trials declining from 81% to 53% and the proportion of approvals supported by at least 1 trial using a comparator declining from 96% to 83%. Meanwhile, it has become more rigorous in other ways, with the proportion of indications supported by at least 1 trial of 6 months' duration increasing from 26% to 46%. These findings have implications for patients and clinicians making decisions about whether to use products newly available on the market as well as clarifying the need for continued evaluation of the safety and efficacy of therapeutics after approval.

A key question is whether these overall trends are driven by changes in the baseline characteristics of drug approvals (eg, the frequency with which approvals use special regulatory programs or orphan designation) or whether there has been an evolution in the standards needed to secure approval within these strata. Our findings suggest both explanations may play a role. We found a significant increase in the proportion of new indications approved using any special regulatory program or orphan designation, in line with previous reports.^[@zoi200159r7]^ These changes likely contribute to the trends we observed in clinical trial evidence supporting approvals, given that the use of special regulatory programs and orphan designation are both associated with more flexible standards for approval.^[@zoi200159r5],[@zoi200159r19]^ However, we also found changes in the aggregated evidence over time even when accounting for use of these programs, suggesting potential involvement of factors beyond compositional effects. There was a decrease in the number of pivotal trials supporting an indication approval only among therapeutics using a special regulatory program, while therapeutics not using a special regulatory program showed increases in the aggregated number of treated patients and the proportion of indications supported by a trial of at least 6 months' duration. These trends were consistent when examining individual associations with Priority Review, Accelerated Approval, and orphan designation, which were used in all 3 periods studied.

These divergent patterns in evidentiary requirements highlight the trade-offs in premarket evidence development inherent to special regulatory programs and orphan status. These programs are intended to encourage development in areas of particular unmet need and, accordingly, to facilitate approvals based on fewer trials, shorter trials, or trials using surrogate markers, thus requiring less time to ascertain an effect and enabling products to reach the market sooner. Yet the use of these programs has especially proliferated in the new development paradigm of precision medicine, which is defined by narrow target populations, some applications of which may fall outside conventional definitions of unmet need.^[@zoi200159r20]^ Given the corresponding trade-offs in premarket evidence, this has led to increased scrutiny regarding whether the programs' flexibility in standards are being appropriately applied, especially in cases in which therapeutics are eventually used for indications much broader than those initially approved.^[@zoi200159r21],[@zoi200159r22],[@zoi200159r23]^

These issues may continue to intensify as the pipeline for precision medicine matures, and they also highlight the importance of a life cycle approach to evaluating drug efficacy and safety in today's regulatory environment.^[@zoi200159r24]^ Prior studies^[@zoi200159r25],[@zoi200159r26]^ have shown that the FDA is more likely to take postmarket safety actions, such as issuing a black box warning or safety communication, for drugs and biologics that received Accelerated Approval or underwent Priority Review. In the context of more flexible premarket standards for evaluation, proponents of this approach embrace the use of postmarketing studies,^[@zoi200159r8]^ pragmatic trials, and real-world evidence (RWE) to ensure continued evidence development for new medical products. In part spurred by the 21st Century Cures Act, the FDA has particularly embraced the use of RWE, defined expansively to include clinical evidence from a variety of settings, including electronic health records, insurance claims, registries, and personal devices, as a new frontier of regulatory science.^[@zoi200159r27]^ In the past few years, the FDA has furthered the integration of RWE into its medical product evaluation process, issuing guidance on the use of RWE in decision-making about drugs, biologics, and devices.^[@zoi200159r28],[@zoi200159r29]^ Continued development of life cycle evaluation methods, including enhanced requirements that ensure studies are undertaken and reported, may strengthen efforts to generate clinical evidence on the safety and efficacy of drugs and biologics after approval to inform patients, clinicians, and regulators.

Limitations {#H2-10-ZOI200159}
-----------

Our study has several limitations. First, our study included only 3-year samples of approvals in each period and cannot capture the full range of therapeutic agents and variations in approval trends across entire decades. Secular trends influenced the number of approvals in any given year, and more reduced sample sizes in certain years also influenced the certainty in our evaluation of trends over time. Second, given our sample, we could not fully adjust for associations between all combinations of drug attributes and special regulatory programs and orphan status. For instance, it was not uncommon for a therapeutic approval to use multiple special regulatory programs, and we could not fully account for the possibility that a single regulatory program or attribute had disproportionate influence on the associations observed. However, the consistency of our findings regarding special regulatory programs across multiple individual special regulatory programs as well as orphan designation suggests that we were able to capture major trends. Third, we included only clinical trials identified as pivotal trials in our study. Other nonpivotal studies and data, such as observational studies or previous marketing experience from other countries, may contribute to FDA reviewers' holistic evaluations of drugs under consideration in ways that cannot be captured by our approach.

Conclusions {#H1-5-ZOI200159}
===========

The findings of this study suggest that quality of clinical trial evidence used to support new drug and biologic approvals has changed during the past 3 decades, requiring fewer pivotal trials with less robust comparators but with longer durations. This change has implications for physicians and patients as they consider using newly approved drugs as well as for regulators, given that it suggests an increasing need for continued evaluation of therapeutic safety and efficacy after approval.
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**eTable 2.**Randomization and Blinding of Pivotal Trials Supporting New Drugs and Biologics Approved by the US Food and Drug Administration in 1995-1997, 2005-2007, and 2015-2017, Overall and Limited to Trials with Comparator Arms
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**eTable 4.**Availability of Information Within Requested Documents for Specific Pivotal Trial Characteristics for New Drugs and Biologics Approved by the US Food and Drug Administration in 1995-1997, Overall and Stratified by Special Regulatory Program and Orphan Designation
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**eTable 8.** Characteristics of Pivotal Trials Supporting New Drugs and Biologics Approved by the US Food and Drug Administration in 1995-1997, 2005-2007, and 2015-2017, Stratified by Therapeutic Area

**eTable 9.**Characteristics of Aggregated Pivotal Trials Supporting New Drug and Biologic Indications Approved by the US Food and Drug Administration in 1995-1997, 2005-2007, and 2015-2017, Stratified by Therapeutic Area
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**eTable 11.**Duration of Aggregated Pivotal Trials Supporting New Drug and Biologic Indications Approved by the US Food and Drug Administration in 1995-1997, 2005-2007, and 2015-2017, Overall and Stratified by Expected Length of Treatment

**eTable 12.**Characteristics of Pivotal Trials Supporting New Drugs and Biologics Approved by the US Food and Drug Administration in 1995-1997, 2005-2007, and 2015-2017, Stratified by Use of Priority Review and Accelerated Approval

**eTable 13.**Characteristics of Aggregated Pivotal Trials Supporting New Drugs and Biologic Indications Approved by the US Food and Drug Administration in 1995-1997, 2005-2007, and 2015-2017, Stratified by Use of Priority Review and Accelerated Approval

**eTable 14.**Characteristics of Pivotal Trials Supporting New Drugs and Biologics Approved by the US Food and Drug Administration in 1995-1997, 2005-2007, and 2015-2017, Stratified by Use of Any Special Regulatory Program, Considering Orphan Designation as a Special Regulatory Program

**eTable 15.**Characteristics of Aggregated Pivotal Trials Supporting New Drugs and Biologic Indications Approved by the US Food and Drug Administration in 1995-1997, 2005-2007, and 2015-2017, Stratified by Use of Any Special Regulatory Program, Considering Orphan Designation as a Special Regulatory Program
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